Dechra acquires the rights to Laverdia™-CA1 (verdinexor tablets)
Thursday, January 13, 2022
Dechra Veterinary Products is pleased to announce that Dechra has acquired the rights to Laverdia™-CA1 (verdinexor tablets) from Anivive Lifesciences, Inc.
Under the terms of the agreement, Dechra will begin selling, marketing and supporting Laverdia-CA1 in the United States in the first quarter of 2022. The product is a novel, oral SINE (selective inhibitor of nuclear export) drug and is the first oral tablet for canine lymphoma. It was conditionally approved by the FDA Center for Veterinary Medicine in January 2021.
Mike Eldred, Dechra’s President of North American Operations commented, “We are excited to acquire the worldwide rights to Laverdia and add this state-of-the-art drug immediately to our U.S. portfolio. Dechra’s commercial and veterinary technical teams currently support veterinarians with highly technical drugs, and Laverdia-CA1 is a perfect fit into our product range.”
Dechra’s companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care. Our brands include Vetoryl® Capsules (trilostane), Zycortal® Suspension (desoxycorticosterone pivalate injectable suspension), Felimazole® Coated Tablets (methimazole), the Vetivex® line of parenteral fluids, and Phycox® joint health supplements. Osurnia® (florfenicol, terbinafine, betamethasone acetate) and the TrizUltra+Keto®, MiconaHex+Triz®, MalAcetic®, and oral anti-infective product lines, including Marboquin® (marbofloxacin) Tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension, spotlight the dermatology offerings. And the recent addition of Mirataz® (mirtazapine transdermal ointment), Porus® One, and Redonyl® Ultra Feline to the portfolio supports the underserved feline market.
LAVERDIA-CA1 is a new oral treatment option for canine lymphoma. It is the first small-molecule selective inhibitor of nuclear export (SINE) drug specifically designed for veterinarian use. It employs a novel targeted mechanism of action where it targets and binds to Exportin 1 (XPO1) - "transport" protein that proliferates in certain types of cancer. Excessive amounts of XPO1 export important tumour suppressing proteins (TSPs)—necessary for fighting cancer—from the nuclei of cells, rendering them vulnerable to uncontrolled growth. With its targeted blocking of XPO1, LAVERDIA-CA1 allows for TSPs to be trapped inside the cell nucleus, triggering programmed cell death of lymphoma cells while sparing healthy cells.
Full Prescribing Information can be found at anivive.com/laverdia.